Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Klein, M. Kampmann, H. Baum, T. Rauscher, T. Vuković, K. Hallermayer, H. Rehner, M. Müller-Bardorff, Katus Ha (1998)
Clinical performance of the new cardiac markers troponin T and CK-MB on the Elecsys 2010. A multicentre evaluation.Wiener klinische Wochenschrift, 110 Suppl 3
R. Christenson, Robin Vollmer, E. Ohman, S. Peck, Trevor Thompson, S. Duh, Stephen Ellis, L. Newby, Topol Ej, R. Califf (2000)
Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group.The American journal of cardiology, 85 5
G. Bernardi (2000)
[Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction].Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 1 11
E. Diderholm, B. Andrén, G. Frostfeldt (2002)
ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery diseaseAcc Current Journal Review, 11
Thomas Fitzmaurice, Charles Brown, Nader Rifai, Alan Wu, Kiang-Teck Yeo (1998)
False increase of cardiac troponin I with heterophilic antibodies.Clinical chemistry, 44 10
C. Zugck, M. Nelles, H. Katus, P. Collinson, D. Gaze, B. Dikkeschei, E. Gurr, W. Hayen, M. Haass, C. Hechler, V. Hoof, K. Guerti, Carl Waes, G. Printzen, K. Klopprogge, Ilse Schulz, R. Zerback (2006)
Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole bloodClinical Chemistry and Laboratory Medicine (CCLM), 44
C. Mueller, A. Scholer, K. Laule-Kilian, B. Martina, C. Schindler, P. Buser, M. Pfisterer, A. Perruchoud (2004)
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.The New England journal of medicine, 350 7
M. Gomez, Jeffrey Anderson, L. Karagounis, J. Muhlestein, F. Mooders (1996)
An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO).Journal of the American College of Cardiology, 28 1
D. Morrow, C. Cannon, R. Jesse, L. Newby, J. Ravkilde, A. Storrow, A. Wu, R. Christenson, F. Apple, G. Francis, Wilson Tang (2007)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes.Clinical chemistry, 53 4
Alan Wu, Jonathan Clive (1997)
Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain.Clinical chemistry, 43 2
Deepak Bhatt, M. Roe, E. Peterson, Yun Li, A. Chen, R. Harrington, A. Greenbaum, P. Berger, C. Cannon, D. Cohen, C. Gibson, J. Saucedo, N. Kleiman, J. Hochman, W. Boden, R. Brindis, W. Peacock, Sidney Smith, C. Pollack, W. Gibier, E. Ohman (2004)
Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement InitiativeJAMA, 292
F. Apple, H. Quist, P. Doyle, Angela Otto, M. Murakami (2003)
Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations.Clinical chemistry, 49 8
A. Storrow, F. Apple, A. Wu, R. Jesse, G. Francis, R. Christenson, C. Cannon, D. Morrow, L. Newby, J. Ravkilde, W. Tang (2007)
National academy of clinical biochemistry laboratory medicine practice guidelines: Point of care testing, oversight, and administration of cardiac biomarkers for acute coronary syndromesPoint of Care: The Journal of Near-patient Testing & Technology, 6
P. Berger, Stephen Ellis, D. Holmes, C. Granger, D. Criger, A. Betriu, E. Topol, R. Califf (1999)
Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial.Circulation, 100 1
D. Gaze, P. Collinson, M. Haass, U. Derhaschnig, M. Hirschl, H. Katus, F. Chwallek, M. Mueller-Bardorff, J. Kellett, Jordi ez-Llanos, Miquel -Bel, Javier ola, Christer n, Ilse Schulz, R. Zerback (2004)
The Use of a Quantitative Point-of-Care System Greatly Reduces the Turnaround Time of Cardiac Marker DeterminationPoint of Care: The Journal of Near-patient Testing & Technology, 3
B. Brodie, T. Stuckey, T. Wall, G. Kissling, C. Hansen, D. Muncy, R. Weintraub, T. Kelly (1998)
Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction.Journal of the American College of Cardiology, 32 5
G. Kost, N. Tran (2005)
Point-of-Care Testing and Cardiac Biomarkers: The Standard of Care and Vision for Chest Pain Centers.Cardiology clinics, 23 4
B. Tardiff, R. Califf, J. Tcheng, A. Lincoff, K. Sigmon, R. Harrington, K. Mahaffey, E. Ohman, P. Teirstein, J. Blankenship, M. Kitt, E. Topol (1999)
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.Journal of the American College of Cardiology, 33 1
P. Collinson, B. Jørgensen, C. Sylvén, M. Haass, F. Chwallek, H. Katus, M. Müller-Bardorff, U. Derhaschnig, M. Hirschl, R. Zerback (2001)
Recalibration of the point-of-care test for CARDIAC T Quantitative with Elecsys Troponin T 3rd generation.Clinica chimica acta; international journal of clinical chemistry, 307 1-2
F. Apple, M. Murakami (2005)
Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction.Clinical chemistry, 51 2
P. Grande, B. Hansen, C. Christiansen (1982)
Estimation of Acute Myocardial Infarct Size in Man by Serum CK‐MB MeasurementsCirculation, 65
M. Panteghini, F. Pagani (2004)
AACC creatine kinase MB (CK-MB) standardization material used as manufacturer's working calibrator is unable to harmonize CK-MB results between two commercial immunoassays.Clinical chemistry, 50 9
O. Sonntag, A. Scholer (2001)
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studiesAnnals of Clinical Biochemistry, 38
J. Alpert, E. Antman, F. Apple, P. Armstrong, J. Bassand, A. Luna, G. Beller, G. Breithardt, B. Chaitman, P. Clemmensen, E. Falk, M. Fishbein, M. Galvani, A. Garson, C. Grines, C. Hamm, B. Nauheim, U. Hoppe, A. Jaffe, H. Katus, J. Kjeksus, W. Klein, P. Klootwijk, C. Lenfant, D. Levy, R. Levy, R. Luepker, F. Marcus, U. Naslund, M. Ohman, O. Pahlm, P. Poole‐Wilson, R. Popp, K. Pyôrâlà, J. Ravkilde, N. Rehnquist, W. Roberts, R. Roberts, J. Roelandt, L. Rydén, S. Sans, M. Simoons, K. Thygesen, H. Tunstall-Pedoe, R. Underwood, B. Uretsky, F. Werf, L. Voipio‐Pulkki, G. Wagner, L. Wallentin, W. Wijns, D. Wood (2000)
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.Journal of the American College of Cardiology, 36 3
W. Boden, R. O'rourke, M. Crawford, A. Blaustein, P. Deedwania, R. Zoble, L. Wexler, R. Kleiger, C. Pepine, D. Ferry, B. Chow, P. Lavori (1999)
Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators.The New England journal of medicine, 338 25
(2001)
Multicenter evaluation of a new pointof-care test for the quantitative determination of Ddimer
P. Collinson, C. John, S. Lynch, A. Rao, R. CANEPA-ANSON, E. Carson, D. Cramp (2004)
A prospective randomized controlled trial of point-of-care testing on the coronary care unitAnnals of Clinical Biochemistry, 41
D. Novis, B. Jones, J. Dale, M. Walsh (2009)
Biochemical markers of myocardial injury test turnaround time: a College of American Pathologists Q-Probes study of 7020 troponin and 4368 creatine kinase-MB determinations in 159 institutions.Archives of pathology & laboratory medicine, 128 2
A. Dasgupta, S. Banerjee, P. Datta (1999)
False-positive troponin I in the MEIA due to the presence of rheumatoid factors in serum. Elimination of this interference by using a polyclonal antisera against rheumatoid factors.American journal of clinical pathology, 112 6
F. Apple, Adrine Chung, Mary Kogut, Susan Bubany, M. Murakami (2006)
Decreased patient charges following implementation of point-of-care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit.Clinica chimica acta; international journal of clinical chemistry, 370 1-2
L. Holmvang, P. Clemmensen, B. Lindahl, B. Lagerqvist, P. Venge, G. Wagner, L. Wallentin, P. Grande (2003)
Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment.Journal of the American College of Cardiology, 41 6
Deepak Bhatt, E. Topol (2000)
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.JAMA, 284 12
C. Ricós, V. Álvarez, F. Cava, J. García-Lario, A. Hernandez, C. Jiménez, J. Minchinela, C. Perich, M. Simón (1999)
Current databases on biological variation: pros, cons and progress.Scandinavian journal of clinical and laboratory investigation, 59 7
(2005)
Point-of-care testing and cardiac biomarkers: the standard of care and vision for chest pain
R. Roberts, P. Henry, B. Sobel (1975)
An Improved Basis for Enzymatic Estimation of Infarct SizeCirculation, 52
(2004)
HA, et al., for the CARMYT Multicentre Study Group. Use of a quantitative point-of-care system greatly reduces the turnaround time of cardiac marker determination
M. Müller-Bardorff, C. Sylvén, G. Rasmanis, B. Jørgensen, P. Collinson, U. Waldenhofer, M. Hirschl, A. Laggner, W. Gerhardt, G. Hafner, I. Labaere, R. Leinberger, R. Zerback, H. Katus (2000)
Evaluation of a Point-of-Care System for Quantitative Determination of Troponin T and Myoglobin, 38
(2006)
Use of cardiac biomarkers for acute coronary syndromes. In: Nichols JH, editor. Laboratory medicine practice guidelines: evidence-based practice for point-ofcare testing
D. Cox, G. Stone, C. Grines, T. Stuckey, P. Zimetbaum, J. Tcheng, M. Turco, Eulogio García, G. Guagliumi, Robert Iwaoka, R. Mehran, W. O’Neill, A. Lansky, J. Griffin (2006)
Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).The American journal of cardiology, 98 3
T. Bertsch, B. Dikkeschei, E. Gurr, W. Hayen, B. Jørgensen, J. Lotz, M. Müller-Bardorff, J. Ordóñez‐Llanos, Ilse Schulz, J. Spinke, M. Thiele, R. Zerback (2007)
Development and calibration of a new point-of-care test for the determination of NT-proBNP in whole blood.Clinical laboratory, 53 7-8
S. Sieck (2006)
The Evolution of a New Standard of Hospital Care: Paradigm Shift to the Emergency Department and the Role of Point-of-Care TestingPoint of Care: The Journal of Near-patient Testing & Technology, 5
A. Singer, Joshua Ardise, J. Gulla, Julie Cangro (2005)
Point-of-care testing reduces length of stay in emergency department chest pain patients.Annals of emergency medicine, 45 6
Abstract Background : The point-of-care (POC) test Roche CARDIAC CK-MB is a new assay which has been developed for the existing Roche Cardiac reader system. Methods : We performed a multicentre evaluation at six sites to assess the analytical performance of the POC CK-MB assay and to compare it with a quantitative laboratory CK-MB assay. Results : Within-series coefficients of variation (CV) resulting from 34 ten-fold measurements with patient samples ranged from 4.3% to 16.4%. Using quality control material, the mean CV values for day-to-day imprecision were 6.5% for the low level control and 8.4% for the high level control. Based upon 847 pairs of values, the mean relative bias of three independently calibrated lots of the POC CK-MB assay ranged from –6% to –11% in method comparisons with the lab CK-MB assay. The mean relative lot-to-lot differences of POC CK-MB were between –2% and +1%. No interference was observed with lipaemic blood (triglyceride concentrations up to 8.1 mmol/L), icteric blood (bilirubin concentrations up to 513 μmol/L), haemolytic blood (haemoglobin concentrations up to 0.12 mmol/L), biotin (up to 30 mg/L) and rheumatoid factor (up to 119 IU/mL), or with 53 standard or cardiological drugs even in toxic concentrations. There was no influence on the results by varying haematocrit values in the range from 21% to 54%. A slight interference with human anti-mouse antibodies type 2 was found. No significant influence on the results with POC CK-MB was found by using sample volumes between 135 and 165 μL. High CK-MB concentrations above the measuring range of POC CK-MB (1–40 μg/L) did not lead to false low results due to potential high-dose hook effect. No significant effect of sample age on recovery occurred up to a sample age of 24 h. No cross-reactivity was found between the POC CK-MB assay and either CK-MM or CK-BB. A substudy with healthy individuals confirmed the reference limits of 3.8 μg/L for females and 6.7 μg/L for males. Conclusions : The POC CK-MB assay showed a very good analytical performance with an excellent concordance with the calibration and reference laboratory method. It should be therefore suitable for its intended use in POC settings. Clin Chem Lab Med 2008;46:630–8.
Clinical Chemistry and Laboratory Medicine (CCLM) – de Gruyter
Published: May 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.